DAFTAR PUSTAKA

1. Khan M, Khan H, Khan S, Nawaz M. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study. Journal of Medical Microbiology. 2020;69:1114-1123.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Pr*event*ion. JAMA. 2020; published online February 24.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; published online January 24.
4. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157–160.
5. WHO Coronavirus (COVID-19) : 1 Juni 2021 2021 [Available from: https://covid19.who.int/.
6. Our World in Data, Statistics and Research Coronavirus Pandemic (COVID-19) : 8 Juli 2021 2021 [Available from: https://ourworldindata.org/coronavirus.
7. Muhamad SV. Pandemi COVID-19 sebagai Persoalan Serius Banyak Negara di Dunia. Pusat Penelitian Badan Keahlian DPR RI. 2021;8(13):7-12.
8. Dinas Komunikasi dan Informasi Provinsi Sumatera Barat. Data Pantauan COVID-19 Provinsi Sumatera Barat 2020 [Available from: https://corona.sumbarprov.go.id/.
9. Kementerian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-10)-Rev-05. 2020.
10. Geatri D. Lembar Metodoligi: Mengenal Analisis Ketahanan (Survival Analysis). Jurnal Keperawatan Indonesia.2005;9(1):36-40.
11. Sousa GJB, Garces TS, Cestari VRF, Florencio RS, Moreira TMM, Pereira MLD. Mortality and survival of COVID-19. Journal of Epidemiology and Infection. 2020;148(e123):1-6.
12. Santos MM, Lucena EES, Lima KC, Brito AAC, Bay MB, Bonfada D. Survival and predictors of deaths of patients hospitalized due to COVID-19 from a retrospective and multicenter cohort study in Brazil. Journal of Epidemiology and Infection. 2020;148(e198):1-11.
13. Salinas-Escudero G, Carillo-Vega MF, Granados-Garcia V, Martinez-Valverde S, Toledano-Toledano F, Garduno-Espinosa J. A survival analysis of COVID-19 in the Mexican Population. BMC Public Health. 2020;20(1):1-8.

14. Zandkarimi E, Moradi G, Mohsenpour B. The Prognostic Factors Affecting the Survival of Kurdistan Province COVID-19 Patients : A Cross-Sectional Study from February to May 2020. International Journal of Health Policy Management. 2020.
15. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus Disease 2019 in Elderly Patients: Characteristics and Prognostic Factors Based on 4-Week Follow-up. Journal of Infection. 2020;80(6):629-45.
16. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy Clinical Immunology. 2020;146(1):110-118.
17. Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian dengan Penyakit Komorbid COVID-19. Jurnal Keperawatan Silampari. 2020;4(1):48-55.
18. Update Data COVID-19 di Provinsi Sumatera Barat. Dinas Kesehatan Provinsi Sumatera Barat. 2 Juni 2021.
19. World Health Organization. Novel Coronavirus(2019-nCoV) Situation Report - 10. World Health Organization. 2020
20. Data sebaran COVID-19 : 1 Juni 2021 2021 [Available from: https://covid19.go.id.
21. Kleibaum, D. G., and Klein, M. 2005. Survival Analysis: A Self-Learning Text. Second Edition. Springer and Bussiness Media, Inc., New York.
22. Epidemiological group of emergency response mechanism of new coronavirus pneumonia in Chinese Center for Disease Control and Pr*event*ion. Epidemiological characteristics of new coronavirus pneumonia. Chinese Journal of Epidemiology: 2020;41.
23. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, et al. A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: A Study of a Family Cluster. The Lancet. 2020;395:514–523.
24. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054–1062.
25. Wenham C, Smith J, Morgan R. COVID-19: the Gendered Impacts of the Outbreak. The Lancet. 2020;395(10227):846–848.
26. The Lancet. The Gendered Dimensions of COVID-19. The Lancet. 2020;395(10231):1168.
27. Cen Y, Chen X, Shen Y, Zhang XH, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019 a multi centre observational. Clinical Microbiology and Infection. 2020;26:1242-1247.

28. Emami A, Javanmardi F, Akbari A, Kojuri J, Bakhtiari H, Rezaei T, et al. Survival Rate in Hypertensive Patients with COVID-19. Clinical Experimental Hypertension 2021;43(1):77-80.

29. Trignaleli CJ, Ingraham NE, Sparks MA, et al. Antihypertensive drugs and risk of COVID-19. Lancet Respiratory Medicine. 2020;8(5):e30-e31.

30. Handayani WR. Faktor-Faktor Risiko yang Berhubungan dengan COVID-19 : Literature Review. Jurnal Untuk Masyarakat Sehat. 2020;4(2):120-134.

31. Ilpaj SM, Nurwati N. Analisis pengaruh tingkat kematian akibat COVID-19 terhadap kesehatan mental masyarakat di Indonesia. Jurnal Pekerjaan Sosial. 2020;3(1):16-28.

32. Rabb H. Kidney disease in the time of COVID-19 : Major Challenges to Patients Care. The Journal of Clinical Investigation. 2020;130(6):2749-51.

33. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19- infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Annals of Oncology. 2020;31(7):894-901.

34. Ng J, Bakrania K, Falkous C, Russels R. COVID-19 Mortality by Age, Gender, Ethnicity, Obesity, and Other Risk Factors A Comparison Against All-Cause Mortality. 2020.

35. Qin L, Li X, Shi J, Yu M, Wang K, Tao Y, et al. Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan. Journal of Medical Virology. 2020;92(11):2684-92.

36. Sopiyudin DM. Analisis Survival: Dasar-Dasar Teori dan Aplikasi Program Stata. Jakarta: Sagung Seto; 2013.

37. Li Y, Deng W, Xiong H, Li H, Chen Z, Nie Y, et al. Immune-related factors associated with pneumonia in 127 children with coronavirus disease 2019 in Wuhan. Pediatric Pulmonology. 2020;55(9):2354-60.

38. Kundu S, Chauhan K, Mandal D. Survival Analysis of Patients With COVID-19 in India by Demographic Factors: Quantitative Study. JMIR Formative Research. 2021;5(5).e23251.

39. Galvao MHR, Rocalli AG. Factors associated with increased risk of death from covid-19: A survival analysis based on confirmed cases. Revista Brasileira de Epidemiologia. 2020;23(1):1-10.

40. Wei X, Xiao YT, Wang J, Chen R, Zhang W, Yang Y, et al. Sex differences in severity and mortality among patients with COVID-19: evidence from pooled literature analysis and insights from integrated bioinformatic analysis. ArXiv Preprint posted online on March 30, 2020.

41. Jin J, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152.

42. Salvati L, Biagioni B, Vivarelli E, Parronchi PJC, Allergy M. A gendered magnifying glass on COVID-19. 2020;18(1):1-11.

43. Byeon KH, Kim DW, Kim J, Choi BY, Chio B, Cho KD. Factors affecting the survival of early CVID-19 patients in South Korea: An observational study based on the Korean National Health Insurance big data. International Journal of Infections Diseases. 2021;105:588-594.

44. Muniyappa R, Gubbi S.COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physical Endocrinol Metab. 2020;318(5):e736-e741.

45. Pititto BDA, Ferreira SRG. Diabetes and COVID-19: more than the sum of two morbidities. Revista de Saude Publica. 2020;54(54):1-6.

46. Kario K, Morisawa Y, Sokunthasarn A, Turana Y, Chia YC, et al. COVDI-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. The Journal of Clinical Hypertension. 2020;22(7):1109-1119.

47. Azer SA. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes and New Infections. 2020;37(100738):1-8.

48. Yang W, Yan F. Petients with RT-PCR-confirmed COVID-19 and normal shest CT. Journal Radiology. 2020;295(2):E3-E.

49. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Journal The Lancet. 2020;395(10234):1417-8.

50. Lacedonia D, Scioscia G, Santomasi C, Fuso P, et al. Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients. Scientific Report. 2021(11);19251:1-9.

51. Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway apithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55:2000688.

52. Johnston SL. Asthma and COVID-19: is asthma a risk factors for severe outcomes?. National Institue and Health Research.

53. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020.

54. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. 2020;97(5):829-38.

55. Diao B, Feng Z, Wang C, Wang H, Liu L, et al. Human Kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. 2020.

56. Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. 2020;144(5):231-21.

57. Zhou H, Zhang Z, Fan H, Li J, Li M, et al. Urinalysis, but not blood biochemistry, detects the early renal-impairment in patients with COVID-19. MedRxiv. 2020.

58. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: Asystematic review. Diabetes and Metabolic Syndrome: Clinical Research & Reviews. 2020;14:1133-1142.

59. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. Harrisons principles of internal medicine, 18e. New York, NY:McGraw-Hill.2020.

60. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using opensafely. Nature. 2020;584(7821):430-6.

61. Gasparini M, Khan S, Patel JM, et al. Renal impairment and its impact on clinical outcomes in patients who are critically ill with COVID-19: a multicenter observational study. Anaesthesia. 2020;76(3):320-6.

62. Mahmood M. Risk factors associated with mortality in COVID-19 patients : a retrospective case control study. 1-11.

63. Bonanad C, Blas SG, Santabalbina FT, et al. the effect of age on mortality in patients with COVID-19: A meta-analysis with 611,853 subjects. Journal of the American Medical Directors Association. 2020;21(7):915-8.

64. Sherwood L. Fisiologi manusia : dari sel ke sistem. Edisi 8. Dep Physiol Pharmacol Sch Med West Virginia Univ. 2014.

65. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: A meta-analysis. J Community Health. 2020;45(6):1270-82.

66. Sama IE, Ravera A, Santema BT, van Goor H, ter Maaten JM, Cleland JG, et al. Circulating plasma concentrations of ACE2 in men and women with heart failure and effects of renin-angiotensin-aldosteron-inhibitors. 2020;41(19):1810-7.

67. Pititto BDA, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID-19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetology & Metabolic Syndrome. 2020;12(1):75.

68. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Review. 2020;14(4):303-310.

69. Abdi K, Jalilian M, Sarbarzeh PA, Vlaisavljevic. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Research and Clinical Practice. 2020;166(108347):1-13.

70. Holman N, Knighton P, Kar J, Keefe JO, Curley M, Weaver A, Barron E, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinal. 2020;8:823-833.

71. Liang X, Shi L, Wang Y, et al. the association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates. J Infect. 2020;81(3):e44-47.

72. Chen L, Hao G. The role of angiotensin-converting enzyme 2 in corona viruses/influenza viruses and cardiovascular disease. Cardiovasc Res. 2020;0:1-5.

73. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2002;17(5):259-60.

74. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798-800.

75. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;2000547(14p).

76. Mehra MR, Desai SS, Kuy SR, Henry TD. Cardiovascular disease, drug therapy and mortality in COVID-19. N Engld J Med Jun. 2020;308:e102.

77. American Academy of Allergy Asthma & Immunology. An Update on COVID-19 for the Practicing Allergist/immunologist. 2021:1.

78. Serifani G, Parmiginai B, Amerio A, Agugllia A, Sher L, Amore M. The psychological impact of COVID-19 on the mental health in general population. 2020;113(8):229-35.

79. Williamson EJ, Walker EJ, Bhaskaran K, et al. Factors associated with COVID-19 related death. Nature. 2020;584(7821):430-6.

80. Benedetti C, Waldman M, Zaza G, Riella LV, Cravedi P. COVID-19 and the kidneys: an update. Front Med. 2020;7:1-13.

81. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of Infection and Public Health. 2020;13(12):1833-1839.

82. D'Marco L, et al. Coronavirus disease 2019 in chronic kidney disease. Clinical Kidney Journal. 2020;13(3):297-306.